Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Michael J. Hochman, Megan Othus, Robert P. Hasserjian, Alexander J. Ambinder, Andrew M. Brunner, Mary-Elizabeth M. Percival, Christopher S. Hourigan, Ronan Swords, Amy E. DeZern, Elihu H. Estey, Judith E. Karp

Blood (2022) 140 (Supplement 1): 1430–1432.

https://doi.org/10.1182/blood-2022-164739

Published: 2022

Journal Articles

Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

Joshua F Zeidner, MD, Hanna Knaus, MD, Amer M. Zeidan, MBBS, MHS, Amanda Blackford, Raul Montiel-Esparza, MD, Gabrielle T. Prince, MD, Lukasz P. Gondek, MD PhD, Gabriel Ghiaur, MD PhD, Margaret M. Showel, MD, Amy E. DeZern, MD, Keith W. Pratz, MD, B. Douglas Smith, MD, Mark J. Levis, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Howard Streicher, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2018) 132 (Supplement 1): 335.

https://doi.org/10.1182/blood-2018-99-114961

Published: 2018

Journal Articles

Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2016) 128 (22): 2820.

https://doi.org/10.1182/blood.V128.22.2820.2820

Published: 2016

Journal Articles

Acute Myeloid Leukemia (AML) Blasts Influence the Gene Expression Signature and Co-Signaling Receptor Expression of CD8 + T Cells

Hanna A. Knaus, MD, Sofia Berglund, MD PhD, Hubert Hackl, PhD, Raúl Montiel-Esparza, MD, Mark J. Levis, MD PhD, Judith E Karp, MD, Ivana Gojo, MD, Leo Luznik, MD

Blood (2016) 128 (22): 1700.

https://doi.org/10.1182/blood.V128.22.1700.1700

Published: 2016

Journal Articles

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Seongseok Yun, Nicole D. Vincelette, Katherine L. B. Knorr, Luciana L. Almada, Paula A. Schneider, Kevin L. Peterson, Karen S. Flatten, Haiming Dai, Keith W. Pratz, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Andrea E. Wahner Hendrickson, Martin E. Fernandez-Zapico, Scott H. Kaufmann

Blood (2016) 127 (22): 2711–2722.

https://doi.org/10.1182/blood-2015-02-629485

Published: 2016

Includes: Supplemental data

Journal Articles

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Jonathan Allen Webster, MD, Raoul Tibes, MD PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD PhD, Judith E Karp, MD, B. Douglas Smith, MD

Blood (2015) 126 (23): 2563.

https://doi.org/10.1182/blood.V126.23.2563.2563

Published: 2015

Journal Articles

Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Raúl Montiel-Esparza, MD, Hanna A. Knaus, MD, Joshua F. Zeidner, MD, Ante Vulic, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Mark J. Levis, MD PhD, Howard Streicher, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2015) 126 (23): 1351.

https://doi.org/10.1182/blood.V126.23.1351.1351

Published: 2015

Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Blood (2015) 126 (23): 1361.

https://doi.org/10.1182/blood.V126.23.1361.1361

Published: 2015

Journal Articles

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Seongseok Yun, MD PhD, Nicole D. Vincelette, Katherine L. B. Knorr, PhD, Luciana L. Almada, PhD, Paula A. Schneider, Kevin L. Peterson, PhD, Karen S. Flatten, Allan D. Hess, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Martin E. Fernandez-Zapico, MD, Scott H. Kaufmann, MD PhD

Blood (2015) 126 (23): 3705.

https://doi.org/10.1182/blood.V126.23.3705.3705

Published: 2015

Journal Articles

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Hanna A. Knaus, MD, Raúl Montiel-Esparza, MD, Joshua F. Zeidner, MD, Amanda Blackford, ScM, Christopher G. Kanakry, MD, Ante Vulic, MD, Mark J. Levis, MD PhD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2015) 126 (23): 3849.

https://doi.org/10.1182/blood.V126.23.3849.3849

Published: 2015

Journal Articles

Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation

Keith W. Pratz, MD, Ivana Gojo, MD, Judith E. Karp, MD, Leo Luznik, MD, B. Douglas Smith, MD, Richard J Jones, MD, Jackie Greer, RN, Christopher Gocke, MD, Maria R. Baer, MD, Vu H. Duong, MD, John J Wright, MD PhD, Michelle A. Rudek, PharmD, PhD, Ashkan Emadi, MD, PhD, Mark J. Levis, MD PhD

Blood (2015) 126 (23): 3164.

https://doi.org/10.1182/blood.V126.23.3164.3164

Published: 2015

Journal Articles

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

Blood (2015) 125 (4): 658–667.

https://doi.org/10.1182/blood-2014-04-571786

Published: 2015

Includes: Supplemental data

Journal Articles

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Mark R. Litzow, MD, Xin Victoria Wang, PhD, Martin P. Carroll, MD, Judith E. Karp, MD, Rhett Ketterling, MD, Scott H. Kaufmann, MD PhD, Hillard M. Lazarus, Selina M. Luger, MD, Elisabeth M. Paietta, PhD, Jacob M. Rowe, MD, Jessica K Altman, Keith W Pratz, MD, E. Randolph Broun, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 3742.

https://doi.org/10.1182/blood.V124.21.3742.3742

Published: 2014

Journal Articles

A Comprehensive Assessment of Phase 1 Clinical Trials in Acute Myeloid Leukemia

Joshua F. Zeidner, MD, Judith E. Karp, MD, Amanda Blackford, Jose Mejias, Gary Smith, S. Percy Ivy, MD, Pamela Harris, MD

Blood (2014) 124 (21): 2282.

https://doi.org/10.1182/blood.V124.21.2282.2282

Published: 2014

Journal Articles

Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia

Hanna A. Knaus, MD, Joshua F. Zeidner, MD, Raul Montiel Esparza, MD, Christopher G. Kanakry, Sudipto Ganguly, PhD, Ante Vulic, MD, Amanda Blackford, MS, B. Douglas Smith, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2014) 124 (21): 1065.

https://doi.org/10.1182/blood.V124.21.1065.1065

Published: 2014

Journal Articles

Investigation of MLN4924 Alone and in Combination with Bcl-2 Inhibitors in Hematopoietic Stem Cells and Progenitors in Acute Myelogenous Leukemia

Katherine L. B. Knorr, B. Douglas Smith, MD, Allan D. Hess, PhD, Judith E. Karp, MD, Scott H. Kaufmann, MD PhD

Blood (2014) 124 (21): 3603.

https://doi.org/10.1182/blood.V124.21.3603.3603

Published: 2014

Journal Articles

Reason for CPXcitement in AML

Joshua F. Zeidner, Judith E. Karp

Blood (2014) 123 (21): 3211–3212.

https://doi.org/10.1182/blood-2014-04-568725

Published: 2014

Journal Articles

A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia

Hetty E Carraway, MD, MBA, Judith E. Karp, MD, Ivana Gojo, MD, Keith W. Pratz, MD, Nilanjan Ghosh, MD, PhD, Steven D. Gore, MD, Margaret M. Showel, MD, Mark Levis, MD, PhD, B. Douglas Smith, Jacqueline Greer, James G. Herman, MD, Lia Gore, MD, Min-Jung Lee, PhD, Sunmin Lee, PhD, Peter Ordentlich, PhD, Richard Piekarz, MD, PhD, Jane Trepel, PhD

Blood (2013) 122 (21): 1427.

https://doi.org/10.1182/blood.V122.21.1427.1427

Published: 2013

Journal Articles

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, MD, Jonathan M. Gerber, MD, Amanda Blackford, Mark Litzow, MD, Matthew C. Foster, MD, Lawrence E. Morris, Jr., MD, Ivana Gojo, MD, Jeffrey E. Lancet, MD, Prithviraj Bose, MD, Raoul Tibes, MD, Stephen A. Strickland, MD, MSCI, Jacqueline M Greer, RN, Michelle Drye, Kevin Meads, Austin Doyle, MD, Richard F Little, MD, MPH, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 47.

https://doi.org/10.1182/blood.V120.21.47.47

Published: 2012

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

NARROW

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

Acute Myeloid Leukemia (AML) Blasts Influence the Gene Expression Signature and Co-Signaling Receptor Expression of CD8 + T Cells

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

A Comprehensive Assessment of Phase 1 Clinical Trials in Acute Myeloid Leukemia

Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia

Investigation of MLN4924 Alone and in Combination with Bcl-2 Inhibitors in Hematopoietic Stem Cells and Progenitors in Acute Myelogenous Leukemia

Reason for CPXcitement in AML

A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only